65,437 trials
Pulmonary Disease, Chronic Obstructive
Primary: Performance Domain of the Patient Satisfaction and Preference Questionnaire (PASAPQ) After 4 Weeks of Treatment — 79.830; 85.112 Scores on a scale — p=0.007
Fever · Infection · Inflammation
Primary: Number of Participants With Clinically-assigned Retrospective Phenotype — 655; 0 Participants
Malaria
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of L9LS Product Administration — 2; 3; 3; 4 Participants
Genitourinary Syndrome of Menopause (GSM)
Primary: Change in VSQ Score — -3.3; -3.7 score on a scale
Early Child Development
Primary: Child Developmental Outcomes — 9.5; 9.4; 9.1; 9.1 age-standardized scores on a scale
Migraine Headache
Primary: Number of Participants With Absence of Medication Overuse Headaches (MOH) at Month 6 — 102; 117; 134 Participants — p=0.13
Comprehension · Informed Consent
Primary: Comprehension of the NEAT Form — 10.6; 10.2 score on a scale
Alzheimer's Disease and Related Dementias
Primary: Pain as Assessed by the Mobilization-Observation-Behavior-Intensity-Dementia (MOBID-2) Scale — -2.70; -.40 score on a scale
Urothelial Carcinoma
Primary: Objective Response Rate (ORR) Based on RECIST 1.1 (Substudies 1,3,4 and 5) — 9.4; 0.0; 14.3; 0.0 Percentage of participants
Overactive Bladder
Primary: Numeric Pain Rating Scale (NPRS) — 4; 3 score on a scale
Healthy Volunteers
Primary: Nicotine Cmax — 5.154; 7.856; 9.553; 12.51 ng/mL
Cancer · Coping Skills · Coping Behavior
Primary: Feasibility: Retention Rate — 31; 31 Participants
Perinatal Depression
Primary: Change in Primary Health Questionnaire (PHQ-9) — 10.68; 10.24; 5.78; 7.48 score on a scale — p=.003
Essential Tremor
Primary: TRG (Tremor Research Group) Essential Tremor Rating Assessment Scale (TETRAS) Subset Score — 12.6; 9.8; -2.8 score on a scale
Cystic Fibrosis
Primary: Metabolic Clearance of D6-25(OH)D3 — 397; 342 mL/day